Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICS: Sintilimab + IL-2 + CAPOX for Rectal Cancer
NCT06108596Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, aldesleukin in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Started Oct 2023; status: completed.
02
Drugs
sintilimabaldesleukin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06108596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108596.